Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02252406 · ClinicalTrials.gov registry record · Phase 4
Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome
A Phase 4 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
NCT02252406: Completed Phase 4 study, sponsored by University of Florida.
NCT02252406 is a Phase 4 study that has completed, run by University of Florida. The registered enrollment target is 33 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02252406, a Phase 4 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of ranolazine on different markers of cardiometabolic disease in women with stable angina.
Primary Outcome
Will evaluate the impact of ranolazine in HgbA1C in women with Metabolic Syndrome (MBS)
Interventions
- OTHER Placebo
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2015-09 |
| Est. Completion | 2019-05-17 |
| Phase | Phase 4 |
What the finished NCT02252406 record still lists
NCT02252406 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02252406 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02252406 about?
NCT02252406 is a clinical study titled "Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome". The purpose of this study is to determine the effects of ranolazine on different markers of cardiometabolic disease in women with stable angina.
What is the current status of trial NCT02252406?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2015-09. Estimated completion is 2019-05-17.
What interventions are being tested in trial NCT02252406?
The interventions under investigation include: Placebo (OTHER), Ranolazine (DRUG).
Who is sponsoring clinical trial NCT02252406?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02252406's enrollment target sits among peer trials
33 1528th of 2000 higher than 467 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia